Impact of type 2 diabetes on glucokinase diabetes (GCK-MODY) phenotype in a Roma (Gypsy) family - Case report

Endocrine Regulations

Volumn 46, Issue 2, 2012, Pages 99-105

  Stanik, J ^a,b   Kusekova, M ^c   Huckova, M ^a   Valentinova, L ^a   Masindova, I ^a   Stanikova, D ^a,b   Ferenczova, J ^c   Gasperikova, D ^a,d   Klimes, I ^a,d  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

^d INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Coincidence; GCK MODY; Glucokinase; Monogenic diabetes; T2D

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; ENALAPRIL; GENOMIC DNA; GLIBENCLAMIDE; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; DNA EXTRACTION; DYSLIPIDEMIA; FAMILY HISTORY; GENE MUTATION; GENOTYPE; GIPSY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; ETHNOLOGY; FAMILY HEALTH; FEMALE; GENETICS; PEDIGREE; PREVALENCE; RISK FACTOR; SLOVAKIA; STATISTICS;

ADULT; DIABETES MELLITUS, TYPE 2; FAMILY HEALTH; FEMALE; GENOTYPE; GLUCOKINASE; GYPSIES; HUMANS; MALE; PEDIGREE; PHENOTYPE; PREVALENCE; RISK FACTORS; SLOVAKIA; YOUNG ADULT;

EID: 84865293939     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2012_02_99     Document Type: Article

References (21)

1. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 35 Suppl 1, S64-71, 2012. http://dx.doi.org/10.2337/dc12-s064
2. Awa WL, Schober E, Wiegand S, Herwig J, Meissner T, Schmidt F, Molz E and Holl RW: Reclassification of diabetes type in pediatric patients initially classified as type 2 diabetes mellitus: 15 years follow-up using routine data from the German/Austrian DPV database. Diabetes Res Clin Pract 94, 463-467, 2011. http://dx.doi.org/10.1016/j.diabres.2011.09.011
3. Ellard S, Bellanne-Chantelot C and Hattersley AT: Best practice guidelines for the molecular genetic diagnosis of maturityonset diabetes of the young. Diabetologia 51, 546-553, 2008. http://dx.doi.org/10.1007/s00125-008-0942-y
4. Gasperikova D, Tribble ND, Stanik J, Huckova M, Misovicova N, van de Bunt M, Valentinova L, Barrow BA, Barak L, Dobransky R, Bereczkova E, Michalek J, Wicks K, Colclough K, Knight JC, Ellard S, Klimes I and Gloyn AL: Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specifc Sp1 binding causing mild fasting hyperglycemia in humans. Diabetes 58, 1929-1935, 2009. http://dx.doi.org/10.2337/db09-0070
5. Gloyn AL: Glucokinase (GCK) mutations in hyperand hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 22, 353-362, 2003. http://dx.doi.org/10.1002/humu.10277
6. Gloyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker L, Ellard S and Holman RR: Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia. Diabetologia 52, 172-174, 2009. http://dx.doi.org/10.1007/s00125-008-1188-4
7. Hattersley A, Bruining J, Shield J, Njolstad P and Donaghue KC: Te diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 10 Suppl 12, 33-42, 2009. http://dx.doi.org/10.1111/j.13995448.2009.00571.x
8. Martin D, Bellanne-Chantelot C, Deschamps I, Froguel P, Robert JJ and Velho G: Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). Diabetes Care 31, 1321-1323, 2008. http://dx.doi.org/10.2337/dc07-2017
9. Massa O, Meschi F, Cuesta-Munoz A, Caumo A, Cerutti F, Toni S, Cherubini V, Guazzarotti L, Sulli N, Matschinsky FM, Lorini R, Iafusco D and Barbetti F: High prevalence of glucokinase mutations in Italian children with MODY. Infuence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetes (SIEDP). Diabetologia 44, 898-905, 2001.
10. Miller SP: Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to common phenotype. Diabetes 48, 1645-1651, 1999. http://dx.doi.org/10.2337/diabetes.48.8.1645
11. Morgan AR: Determining genetic risk factors for pediatric type 2 diabetes. Curr Diab Rep 12, 88-92, 2012. http://dx.doi. org/10.1007/s11892-011-0245-4
12. Murphy R, Ellard S and Hattersley AT: Clinical implications of a molecular genetic classifcation of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4, 200-213, 2008. http://dx.doi.org/10.1038/ncpendmet0778
13. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S and Gloyn AL: Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30, 1512-1526, 2009. http://dx.doi.org/10.1002/humu.21110
14. Pruhova S, Dusatkova P, Sumnik Z, Kolouskova S, Pedersen O, Hansen T, Cinek O and Lebl J: Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations. Pediatr Diabetes 11, 529-535, 2010. http://dx.doi.org/10.1111/j.1399-5448.2010.00646.x
15. Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad PR, Hansen T, Costa A, Conget I, Pedersen O, Sovik O, Lorini R, Groop L, Froguel P and Hattersley AT: Te genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 45, 427-435, 2002. http://dx.doi.org/10.1007/s00125-001-0770-9
16. Tanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, Ellard S, Farmer AJ, McCarthy MI and Owen KR: Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young. Diabetes Care, 2012.
17. Tanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gasperikova D, Szopa M, Tjora E, James TJ, Kokko P, Loiseleur F, Andersson E, Gaget S, Isomaa B, Nowak N, Raeder H, Stanik J, Njolstad PR, Malecki MT, Klimes I, Groop L, Pedersen O, Froguel P, McCarthy MI, Gloyn AL and Owen KR: A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 54, 2801-2810, 2011. http://dx.doi.org/10.1007/s00125-011-2261-y
18. Vaag A and Lund S: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 166, 159-170, 2012. http://dx.doi.org/10.1530/EJE-11-0022
19. Valentinova L, Beer NL, Stanik J, Tribble ND, van de Bunt M, Huckova M, Barrett A, Klimes I, Gasperikova D and Gloyn AL: Identification and functional characterization of novel glucokinase mutations causing Maturity-onset diabetes of the young in Slovakia. PloS One, 2012, in press. http://dx.doi.org/10.1371/journal.pone.0034541
20. Vaxillaire M, Samson C, Cave H, Metz C, Froguel P and Polak M: Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France. Diabetologia 45, 454-455, 2002. http://dx.doi.org/10.1007/s00125001-0741-1
21. Velho G, Blanche H, Vaxillaire M, Bellanne-Chantelot C, Pardini VC, Timsit J, Passa P, Deschamps I, Robert JJ, Weber IT, Marotta D, Pilkis SJ, Lipkind GM, Bell GI and Froguel P: Identification of 14 new glucokinase mutations and description of the clinical profle of 42 MODY-2 families. Diabetologia 40, 217-224, 1997. http://dx.doi.org/10.1007/s001250050666